Ophthalmic Business News

OCS-01 eye drops demonstrated positive topline results for the treatment of inflammation and pain after cataract surgery, according to a press release from Oculis.

The FDA approved Izervay, a complement C5 inhibitor, for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma.

SEATTLE — In this Healio Video Perspective from OIS Retina, Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration.

Most investors, when considering their financial future, have a common number one concern – that they will not have saved enough to sustain them in retirement. In other words, they fear that they will outlive their money.

Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.

SEATTLE — In this Healio Video Perspective from OIS Retina, Ronil Patel, MS, discusses Ocuphire Pharma’s end-of-phase 2 FDA meeting planned for later this year.

SEATTLE — In this Healio Video Perspective from OIS Retina, Richard Small previews a presentation that will cover phase 3 data on encapsulated cell therapy for the treatment of macular telangiectasia.

Verséa Ophthalmics will distribute Celularity’s Biovance and Biovance 3L Ocular products for ocular surface disease treatment and ocular surgical support under the terms of an exclusive U.S. commercialization agreement.

AsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the development of its lead clinical candidate, AXT107, for the treatment of neovascular retinal diseases, according to a press release.

Kodiak Sciences is discontinuing development of tarcocimab tedromer, citing results of the GLEAM and GLIMMER phase 3 studies in diabetic macular edema, according to a press release.